MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
LA JOLLA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury has been selected for a poster presentation at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo to be held March 10 – 14, 2024 in Salt Lake City, Utah. The poster will be presented by MediciNova’s collaborator, Perenlei Enkhbaatar, MD, PhD, FAHA, Professor, Department of Anesthesiology, Director, Translational Intensive Care Unit, Charles Robert Allen Professor in Anesthesiology at The University of Texas Medical Branch.
Related news for (MNOV)
- MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
- MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
- MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
- medicinova announces update of phase 2/3 clinical trial of mn-166 (ibudilast) in als patients (combat-als) at the 2024 annual neals meeting (northeast amyotrophic lateral sclerosis consortium)